One in a million
4 February 2014
Email
Share
An approved gene therapy by uniQure, whose IPO is slated for this week, has an eye-popping cost. It could eliminate a lifetime of hospital trips for sufferers of a rare disease, but it’s hard to say because so few patients have been tested. Even so, it may be rationally priced.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.